AzTrials
AzTrials

Healthy VolunteersPhase 1NCT07613684

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

A Phase 1 study testing MF-300 SAD, MF-300 Food Effect and MF-300 MAD in people with Healthy Volunteers, run by Epirium Bio Inc. at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose [SAD] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose [MAD] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (> 65 to ≤75 years of age) healthy adult subjects. Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Volunteers
What is being tested?
MF-300 SAD, MF-300 Food Effect and MF-300 MAD
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
2 sitesUnited States
Study dates
20 Dec 2024to 9 Oct 2025
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Non-Elderly Cohorts:
  • Healthy male or non-pregnant, non-lactating female subjects ≥ 18 to ≤ 65 years of age at time of first dosing.
  • Body mass index (BMI) within the range ≥ 18.0 to ≤ 35.0 kg/m2.
  • Subjects in the food effect cohort must be willing to eat a high fat breakfast, including butter and turkey bacon or sausage.
  • Female subjects must either:
  • have no childbearing potential by reason of surgery (e.g., hysterectomy, bilateral oophorectomy, salpingectomy in documented medical history) or be at least 1 year post-menopausal (e.g., 12 months without menstrual period without other medical cause), and have menopause confirmed with follicle-stimulating hormone level of >40 IU/L at screening in women not taking hormone contraceptive or hormone replacement therapy. Note: Documentation can come from the study center personnel's: review of the subject's medical records, medical examination, or medical history interview.
Show all 28Show fewer
  • if of child-bearing potential, must be truly abstinent of heterosexual intercourse as their usual and preferred lifestyle practicing abstinence and agree to remain abstinent for the duration of the study or subject's heterosexual partner is non-fertile (e.g. at least 90 days post-vasectomy from screening) or subjects are using and willing to continue using two medically acceptable forms of birth control for at least 30 days prior to screening (at least 90 days for oral and transdermal contraceptives) and at least 30 days after the last study drug administration. Acceptable forms of contraception include: bilateral tubal ligation or occlusion, oral or injectable hormonal contraceptives, contraceptive patch, hormonal and non-hormonal intra uterine devices, vaginal hormonal rings, vaginal diaphragm, or cervical caps, in addition to having their male partner use a condom plus spermicide agent.
  • Male subjects must be non-fertile, vasectomized (vasectomy performed 4 months or more prior to the first dosing), or truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for duration of study and for 90 days from last administration of study drug or heterosexual partner is not of child bearing potential or subject is willing to continue using two medically acceptable form of birth control from Day -1 until at least 90 days after the last administration of study drug. Highly effective contraceptive methods include:
  • Use of a condom plus spermicide agent from the time of informed consent until 90 days after the last administration of study drug.
  • Subject's sexual partner is of non-childbearing potential, i.e., post-menopausal or surgically sterilized
  • If subject's partner is of childbearing potential, she is using an acceptable form of contraception such as: bilateral tubal ligation or occlusion, oral or injectable hormonal contraceptives, contraceptive patch, hormonal and non-hormonal intra uterine devices, vaginal hormonal rings, vaginal diaphragm, or cervical caps
  • Male subjects must agree not to donate sperm from the first dosing until 90 days after the last dose.
  • Capable of giving signed informed consent that includes agreement to comply with the requirements and restrictions listed in the ICF and in this protocol.
  • Elderly Cohorts:
  • To be eligible for this study, subjects must meet all of the following inclusion criteria:
  • Healthy male or non-pregnant, non-lactating female subjects > 65 to ≤ 75 years of age at time of first dosing. Subjects with a history of and/or current well-controlled medical conditions may be enrolled so long as the investigator, in consultation with the medical monitor, are of the opinion that such conditions will not interfere with the safety of the subjects and that the subjects are otherwise in good general health. Some examples of allowable well-controlled medical conditions, in otherwise healthy subjects, include, but are not limited to the following:
  • Well-controlled hypertension, for which, if on medication, are on a stable dose for at least 3 months prior to screening with no history of cardiac arrhythmia
  • Well-controlled pre-diabetes/non-insulin dependent type 2 diabetes managed by diet and exercise. If treated with metformin, on a stable metformin dose for at least 3 months prior to screening
  • Well-controlled hyperlipidemia, for which, if on medication, are on a stable dose for at least 3 months prior to screening
  • Overweight/Obesity not requiring medication
  • Body mass index (BMI) within the range ≥ 18.0 to ≤ 35.0 kg/m2.
  • Female subjects must have no childbearing potential by reason of surgery (e.g., hysterectomy, bilateral oophorectomy, salpingectomy in documented medical history) or be at least 1 year post-menopausal (e.g., 12 months without menstrual period without other medical cause), and have menopause confirmed with follicle-stimulating hormone level of >40 IU/L at screening in women not taking hormone contraceptive or hormone replacement therapy. Note: Documentation can come from the study center personnel's: review of the subject's medical records, medical examination, or medical history interview. Female subjects who do not meet a follicle-stimulating hormone level of >40 IU/L at screening must be truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for the duration of the study, or subject's heterosexual partner is non-fertile (e.g. at least 90 days post-vasectomy from screening), or agrees to use a condom plus spermicide agent from screening to end of study.
  • Male subjects must be non-fertile, vasectomized (vasectomy performed 4 months or more prior to the first dosing), or truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for duration of study and for 90 days from last administration of study drug or heterosexual partner is not of child bearing potential or subject is willing to continue using two medically acceptable form of birth control from Day -1 until at least 90 days after the last administration of study drug. Highly effective contraceptive methods include:
  • Use of a condom plus spermicide agent from the time of informed consent until 90 days after the last administration of study drug.
  • Subject's sexual partner is of non-childbearing potential, i.e., post-menopausal or surgically sterilized
  • If subject's partner is of childbearing potential, she is using an acceptable form of contraception such as: bilateral tubal ligation or occlusion, oral or injectable hormonal contraceptives, contraceptive patch, hormonal and non-hormonal intra uterine devices, vaginal hormonal rings, vaginal diaphragm, or cervical caps
  • Male subjects must agree not to donate sperm from the first dosing until 90 days after the last dose.
  • Capable of giving signed informed consent that includes agreement to comply with the requirements and restrictions listed in the ICF and in this protocol.

Who cannot join

  • Non-Elderly Cohorts:
  • Subjects who meet any of the following criteria will be excluded from participating in the study:
  • History of or current clinically significant medical illness including, but not limited to, any cardiovascular disease (including blood pressure or rhythm disturbance requiring constant monitoring), hematologic disease, coagulation disorders, lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease and diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, or any other illness that the Investigator considers should exclude the subject or that could interfere with the safety of the subjects, or might confound the study results.
  • Has cancer (Note: subject with history of cancer that is in complete remission and not requiring treatment for at least 5 years, including basal cell carcinoma, squamous cell skin cancer, or melanoma in situ superficial skin lesions that have been successfully removed, will not be exclusionary).
  • Has acute or chronic GI conditions (e.g., gastroesophageal reflux disease, peptic ulcer, active and chronic colitis, cholecystectomy, small or large bowel resection, gastric bypass or equivalent) that would interfere with drug tolerance or absorption.
  • Has history of migraine headaches requiring medical attention or active treatment within the past 6 months from screening.
Show all 54Show fewer
  • Has visible sunburn at admission
  • Has a history of hypersensitivity/photosensitivity dermatosis within the past 5 years,
  • Has another active dermatological pathology at screening or admission excluding dry skin or acne, deemed clinically significant by the Investigator.
  • Has a history of or active ocular pathology or clinically significant findings in the Investigator opinion on ophthalmology exam at screening (Note: normal slit exam (glaucoma, cataract) will be sufficient to exclude sensitivity to phototoxicity).
  • Clinically significant abnormalities in results of laboratory tests, such as clinically significant abnormal hematology, clinical chemistry, thyroid, or urinalysis at screening or at the time of admission, as per Investigator's judgment; Note: Repeat testing is allowed at Investigator discretion.
  • Liver impairment defined as AST and/or ALT > ULN; or kidney impairment defined as eGFR < 90 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
  • Clinically significant abnormal physical examination or vital signs as determined by the Investigator.
  • Clinically significant, abnormal 12 lead ECG as determined by the Investigator, including average QTcF > 450 ms for males and >470 ms for females. Note: Repeat testing is allowed at Investigator discretion.
  • Blood pressure less than 90/40 mmHg or greater than 140/90 mmHg. Heart rate lower than 40 bpm or higher than 99 bpm. Subjects should be seated or semi-supine for a minimum of 5 minutes. Vital signs may be repeated once (once at screening and once at admission) at the discretion of the PI or designee.
  • History of or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2) antibody.
  • Active bacterial or viral infection at screening or the time of admission or COVID 19 test positive at admission
  • Excessive use of caffeine-containing foods including coffee, tea, cola, energy drinks or chocolates, exceeding 500 mg caffeine/day (approximately 5 cups of coffee or 10 cups of tea), in the opinion of the Investigator during the 7 days before the first administration of the study drug.
  • Use of or unable to refrain from prescribed medication (with the exception of hormone contraceptives for women of child bearing potential) or over-the-counter (OTC) medicine (including vitamins, and herbal and dietary supplements, such as St John's Wort) during the 14 days or clearance of 5 half-lives (whichever is longer) before the first administration of the study drug and throughout the study.
  • Participation in another investigational drug, biologic, or device study, with less than 30 days or less than 5 half-lives from the last dose of investigational product to admission, whichever is longer, except for observational studies.
  • Use of nicotine-containing products (gum, patch, etc.) within 3 months of Screening (as confirmed by urine cotinine test) and throughout the study; Presence or history within 2 years of screening of smoking or vaping nicotine and throughout the study.
  • Subject has a presence or history, within 2 years of screening, of alcohol abuse or illicit substance abuse as judged by the Investigator or consumes alcohol or an illicit substance within 48 hours prior to admission and throughout the study.
  • Presence or history of marijuana use (including prescribed marijuana) within 30 days of Screening and throughout the study
  • Positive result in the urine alcohol and/or drug screen at screening or at the time of admission.
  • Veins unsuitable for repeated venipuncture.
  • Blood donation or blood loss of more than 500 mL within 7 days prior to screening.
  • In the Investigator's opinion, subject is unable to understand the nature of the study and any risks involved in participation, and unwilling to cooperate and comply with the clinical study protocol procedures, restrictions (dietary or physical activity), and requirements, or is unsuitable for any other reason.
  • Elderly Cohorts:
  • Subjects who meet any of the following criteria will be excluded from participating in the study:
  • Any acute or chronic clinically significant medical condition that is poorly controlled and in the judgement of the Investigator (in consultation with the Sponsor Medical Monitor) could interfere with the safety of the subject or might confound the study results.
  • Has cancer (Note: subject with history of cancer that is in complete remission and not requiring treatment for at least 5 years, including basal cell carcinoma, squamous cell skin cancer, or melanoma in situ. Superficial skin lesions that have been successfully removed, will not be exclusionary).
  • Has acute or chronic GI conditions (e.g., gastroesophageal reflux disease, peptic ulcer, active and chronic colitis, cholecystectomy, small or large bowel resection, gastric bypass or equivalent) that would interfere with drug tolerance or absorption.
  • Has history of migraine headaches requiring medical attention or active treatment within the past 6 months from screening.
  • Has visible sunburn at admission
  • Has a history of hypersensitivity/photosensitivity dermatosis within the past 5 years,
  • Has another active dermatological pathology at screening or admission excluding dry skin or acne, deemed clinically significant by the Investigator.
  • Has a history of or active ocular pathology or clinically significant findings in the Investigator opinion on ophthalmology exam at screening (Note: normal slit exam (glaucoma, cataract) will be sufficient to exclude sensitivity to phototoxicity). Participants with a history of cataracts that have been corrected may be enrolled, just so long as the corrective procedure took place ≥1 yr prior to screening, and current exam shows no active pathology on screening exam.
  • Clinically significant abnormalities in results of laboratory tests, such as clinically significant abnormal hematology, clinical chemistry, thyroid, or urinalysis at screening or at the time of admission, as per Investigator's judgment; Note: Repeat testing is allowed at Investigator discretion.
  • Liver impairment defined as AST and/or ALT > ULN; or kidney impairment defined as eGFR < 75 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation at screening.
  • Clinically significant abnormal physical examination or vital signs as determined by the Investigator.
  • Clinically significant, abnormal 12 lead ECG as determined by the Investigator, including average QTcF > 450 ms for males and >470 ms for females. Note: Repeat testing is allowed at Investigator discretion.
  • Blood pressure less than 90/40 mmHg or greater than 140/90 mmHg. Heart rate lower than 40 bpm or higher than 99 bpm. Subjects should be seated or semi-supine for a minimum of 5 minutes. Vital signs may be repeated once (once at screening and once at admission) at the discretion of the PI or designee.
  • History of or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2) antibody.
  • Active bacterial or viral infection at screening or the time of admission or COVID 19 test positive at admission
  • Excessive use of caffeine-containing foods including coffee, tea, cola, energy drinks or chocolates, exceeding 500 mg caffeine/day (approximately 5 cups of coffee or 10 cups of tea), in the opinion of the Investigator during the 7 days before the first administration of the study drug.
  • Use of or unable to refrain from prescribed medication or over-the-counter (OTC) medicine (including vitamins, and herbal and dietary supplements, such as St John's Wort) during the 14 days or clearance of 5 half-lives (whichever is longer) before the first administration of the study drug and throughout the study. Subjects taking daily prescription medications for management of acceptable chronic medical conditions (as defined in inclusion criteria #1) will be allowed to continue on these medications but must be on a stable dose, as defined by no change in dose for the 3 months prior to the first dose of study medication and no planned changes during the conduct of the study.
  • Participation in another investigational drug, biologic, or device study, with less than 30 days or less than 5 half-lives from the last dose of investigational product to admission, whichever is longer, except for observational studies. This reference is specific to participation in a different study involving another investigational drug. This does not apply to the current study where a participant in the SAD phase of the study can also participate in the MAD phase of the study provided they continue to meet all eligibility criteria and a sufficient washout period of 5 half-lives (minimum of 96 hours) takes place between the first dose of the SAD and first dose of the MAD phases.
  • Use of nicotine-containing products (gum, patch, etc.) within 3 months of Screening (as confirmed by urine cotinine test) and throughout the study; Presence or history within 2 years of screening of smoking or vaping nicotine and throughout the study.
  • Subject has a presence or history, within 2 years of screening, of alcohol abuse or illicit substance abuse as judged by the Investigator or consumes alcohol or an illicit substance within 48 hours prior to admission and throughout the study.
  • Presence or history of marijuana use (including prescribed marijuana) within 30 days of Screening and throughout the study
  • Positive result in the urine alcohol and/or drug screen at screening or at the time of admission.
  • Veins unsuitable for repeated venipuncture.
  • Blood donation or blood loss of more than 500 mL within 7 days prior to screening.
  • In the Investigator's opinion, subject is unable to understand the nature of the study and any risks involved in participation, and unwilling to cooperate and comply with the clinical study protocol procedures, restrictions (dietary or physical activity), and requirements, or is unsuitable for any other reason.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • Site 101

    Austin, Texas, 78744

  • Site 102

    Marlton, New Jersey, 08053

Other trials in United States

About this study

Official title: Phase 1 Study of Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose [SAD] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose [MAD] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (> 65 to ≤75 years of age) healthy adult subjects.

Read the detailed description

Part 1a is a double blind, randomized, placebo controlled, sequential SAD trial in healthy male or female volunteers. Volunteers will receive oral study drug (MF-300 or placebo) single dose administration. The dose levels will be tested sequentially until safety evaluation identifies a non-tolerated dose in the investigated population or when sustained MF-300 plasma levels are reaching the exposure supported by the available preclinical toxicokinetic data. Approximately 5 dose groups (non-elderly population) will provide a series increasing dose levels. An additional SAD dose group will evaluate an elderly population, with a dose selected based on safety and PK data from the 5 non-elderly SAD cohorts but not higher than what has been determined as generally safe and tolerated in the non-elderly population. Overall, no less than 48 subjects (assuming 6 cohorts of 8 subjects each) may complete the SAD study.

One tolerated dose completed in Part 1a will be selected for the evaluation of food effect (Part 1b). The dose will be selected on the basis of accumulated safety and PK information from the SAD phase. Food effect assessment is to be performed using the non-elderly population only. The food effect study is a randomized, 2-period, 2-sequence, open-label, crossover study. Approximately 12 subjects will be randomly assigned to 1 of the 2 treatment sequences (6 subjects per sequence) in which they receive MF-300 following a 10-hour fast or following a high-fat breakfast.

Part 2 is a double blind, randomized, placebo controlled, sequential MAD trial in healthy male or female volunteers. Volunteers will receive oral study drug (MF-300 or placebo) daily for 5 days as anticipated to achieved MF-300 steady state. The frequency of administration (once daily (QD)) and the duration of therapy required to achieve steady state (5 daily doses) were selected on the basis of allometric modeling from available toxicokinetic data but may be adapted based on MF-300 PK observed in the SAD cohorts previously completed. Three dose groups (non-elderly population) will provide a series increasing dose levels. The start of the MAD and SAD parts will be staggered, and a MAD dose cohort may be initiated when the corresponding SAD cohort at the next higher MF-300 dose has been cleared as safe and the food effect cohort has been completed. A fourth MAD dose group will be evaluated in the elderly population.

Being tested
MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD
Keywords
SAD, MAD, Food Effect, Non-Elderly, Elderly

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MF-300 SADDrug

    Also called MF-300

    oral capsule at doses of 75mg, 125 mg, 250 mg, 500 mg, or 800 mg

  • PlaceboDrug

    matching placebo oral capsule

  • MF-300 Food EffectDrug

    Also called MF-300

    oral capsule at a dose of 500 mg

  • MF-300 MADDrug

    Also called MF-300

    oral capsule at doses of 75mg, 125 mg, or 200 mg

Study groups in NCT07613684
Study groupRoleWhat they receive
Part 1a Single Ascending Dose (SAD) MF-300Experimental6 out of 8 participants per cohort (up to 6 cohorts) will be randomized to receive a single dose of MF-300 in a fasted state
Receives: Drug: MF-300 SAD
Part 1a Single Ascending Dose (SAD) PlaceboPlacebo comparator2 out of 8 participants per cohort (up to 6 cohorts) will be randomized to receive a single oral dose of Placebo in a fasted state
Receives: Drug: Placebo
Part 1b Food Effect (Fasted/Fed) MF-300Experimental12 participants will receive a single dose of MF-300 in fed and fasting conditions
Receives: Drug: MF-300 Food Effect
Part 2 Multiple Ascending Dose (MAD) MF-300Experimental8 out of 10 participants per cohort (up to 4 cohorts) will be randomized to receive once daily oral doses of MF-300 on Days 1-5 in a fasted state
Receives: Drug: MF-300 MAD
Part 2 Multiple Ascending Dose (MAD) PlaceboPlacebo comparator2 out of 10 participants per cohort (up to 4 cohorts) will be randomized to receive once daily oral doses of Placebo on Days 1-5 in a fasted state
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of participants with treatment-emergent adverse events (TEAEs)

    Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment

    Measured: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

  2. Proportion of participants with serious adverse events (SAEs)

    An SAE is any untoward medical occurrence at any dose which results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (IME)

    Measured: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

  3. Proportion of participants with any TEAE leading to premature discontinuation of study intervention

    Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment

    Measured: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

Secondary outcomes (9)

  1. Part 1 SAD Cmax

    Plasma PK analysis of maximum observed plasma concentration (Cmax) for MF-300 following a single dose in healthy subjects

    Measured: up to 72 hours

  2. Part 1 SAD Tmax

    Plasma PK time corresponding to the maximum observed plasma concentration (Tmax) for MF-300 following a single dose in healthy subjects

    Measured: up to 72 hours

  3. Part 1 SAD t½

    Plasma PK apparent terminal elimination half-life in plasma (t½) for MF-300 following a single dose in healthy subjects

    Measured: up to 72 hours

  4. Part 1 SAD AUC0-∞

    Plasma PK area under the plasma concentration vs. time curve from time zero extrapolated to infinity (AUC0-∞) for MF-300 following a single dose in healthy subjects

    Measured: up to 72 hours

  5. Part 2 MAD Cmax

    Plasma PK maximum observed plasma concentration (Cmax) for MF-300 following multiple doses in healthy subjects

    Measured: up to Day 6

  6. Part 2 MAD Ctrough

    Plasma PK trough plasma concentration (Ctrough) for MF-300 following multiple doses in healthy subjects

    Measured: up to Day 6

  7. Part 2 MAD Tmax

    Plasma PK time corresponding to the maximum observed plasma concentration (Tmax) for MF-300 following multiple doses in healthy subjects

    Measured: up to Day 6

  8. Part 2 MAD t½

    Plasma PK Plasma apparent terminal elimination half-life in plasma (t½) for MF-300 following multiple doses in healthy subjects

    Measured: up to Day 6

  9. Part 2 MAD AUC0-last

    Plasma PK area under the plasma concentration vs. time curve from time zero to last measurable concentration (AUC0-last) for MF-300 following multiple doses in healthy subjects

    Measured: up to Day 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2026
  2. Study start20 Dec 2024
  3. Primary completion9 Oct 2025
  4. Study completion9 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07613684
Sponsor's protocol ID
MF-300-101
Status last verified
May 2026
First submitted
14 May 2026
Last updated
29 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing MF-300 SAD, MF-300 Food Effect and MF-300 MAD in people with Healthy Volunteers, run by Epirium Bio Inc. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 54 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of participants with treatment-emergent adverse events (TEAEs) (time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07613684.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in